Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.
LivaNova PLC (NASDAQ: LIVN) is a global medical technology company headquartered in London, focused on select neurological and cardiac conditions. This news page aggregates company announcements, clinical updates, investor communications, and other disclosures that LivaNova issues through press releases and related channels.
Readers can find coverage of LivaNova’s neuromodulation activities, including developments in VNS Therapy for Drug‑Resistant Epilepsy and results from the CORE‑VNS real‑world study. News items also describe health economics analyses, reimbursement decisions affecting VNS Therapy procedures under U.S. Medicare programs, and scientific presentations at major epilepsy meetings.
The feed also includes updates on LivaNova’s cardiopulmonary business and its heart‑lung support technologies, as well as information on its work in obstructive sleep apnea through proximal hypoglossal nerve stimulation and the aura6000 investigational system. Articles may highlight data from randomized controlled trials, long‑term follow‑up analyses, and presentations at specialized surgical sleep and medical conferences.
In addition, investors can follow LivaNova’s participation in healthcare investment conferences, Investor Day events, and quarterly financial result announcements, which the company often distributes via press release and webcasts. By reviewing this page, users can track how LivaNova communicates about its core Epilepsy and Cardiopulmonary businesses, its research programs, and its long‑range strategic plans.
For anyone researching LIVN stock or monitoring developments in medical technology for neurological and cardiac conditions, this news page offers a centralized view of LivaNova’s public announcements over time.
LivaNova (Nasdaq: LIVN) will release its first-quarter 2026 results and host a conference call on Wed., May 6, 2026 at 1:00 p.m. London time (8:00 a.m. EDT). The company will publish results before the call.
Investors can access an audiocast at www.livanova.com/events, join by phone using the listed U.S. and international numbers, or listen to a replay on the Investors section immediately after the event. Log on ~10 minutes early for setup. Conference access code: 946097.
LivaNova (Nasdaq: LIVN) received FDA premarket approval for the aura6000 System to treat adults with moderate to severe obstructive sleep apnea (AHI 15–65) who cannot tolerate or are ineligible for PAP therapy. The approval is supported by the OSPREY randomized controlled trial showing a 65% responder rate at 12 months and median AHI reduction from 34.3 to 11.6 events/hour at month 7. LivaNova plans a next‑generation, MRI‑compatible device with rechargeable battery tech targeting first‑half 2027 commercialization, pending FDA supplement review.
LivaNova (Nasdaq: LIVN) reported Q4 2025 revenue of $360.9M (+12.1% reported, +9.5% organic) and full-year 2025 revenue of $1.388B (+10.7% reported, +9.7% constant-currency). The company recorded a GAAP loss per share of $4.45 due to a $365.6M SNIA environmental liability, and adjusted EPS of $3.90. LivaNova issued 2026 guidance: constant-currency revenue growth of 6.0–7.0%, adjusted diluted EPS of $4.15–$4.25, and adjusted free cash flow of $160–$180M. CMS reimbursement for VNS Therapy increased materially, and FDA cleared the company’s cloud-based digital health platform.
LivaNova (Nasdaq: LIVN) will release its fourth-quarter and full-year 2025 results and host a conference call on Wed., Feb. 25, 2026 at 1:00 p.m. London time (8:00 a.m. ET). The company will issue results prior to the call and provide an audiocast at www.livanova.com/events. Telephone access is available at +1 833 470 1428 (U.S.) or +1 929 526 1599 (outside U.S.) using conference code 901145. Listeners are advised to log on ~10 minutes early. A replay will be posted on the Investors section of the LivaNova website immediately after the event.
LivaNova (Nasdaq: LIVN) announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco.
Vladimir Makatsaria, CEO, and Alex Shvartsburg, CFO, will participate in a fireside chat on Wed., Jan. 14, 2026 at 1:30 p.m. Pacific Standard Time. The session will be webcast; registered attendees can access it via www.livanova.com/events. Listeners are advised to log on ~10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) will present eight scientific posters at the American Epilepsy Society Annual Meeting (Dec 5-9, 2025) showcasing real-world evidence from the CORE-VNS study and new health-economics analyses.
Key findings include median seizure reductions up to 95% for the most disabling seizure types at 36 months, early seizure improvements in children by 3 months with sustained benefit to 36 months, a 94% median reduction when VNS was used after 2–3 anti-seizure medications versus 57% after >10 medications, and a >70% decrease in rescue medication use at 36 months. Analyses also report reduced hospitalizations, ED visits and overall costs post-implantation across commercial, Medicare, and Medicaid cohorts.
LivaNova (Nasdaq: LIVN) appointed Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, effective December 1, 2025. Blaise reports to Vladimir Makatsaria, CEO, and joins the Executive Leadership Team.
She brings more than 25 years in medtech and 19 years at ResMed with leadership roles in marketing, sales, strategy, and regional presidency across Europe. Her background includes board roles with MedTech Europe and the Medical Device Innovation Consortium. Blaise holds a bachelor’s in International Business from the University of Sheffield and an MBA from Kedge Business School.
LivaNova (Nasdaq: LIVN) said CFO Alex Shvartsburg will give a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City.
The presentation is scheduled for Tuesday, Dec. 2, 2025 at 1:30 PM ET, available live via webcast at www.livanova.com/events. Listeners are advised to log on about 10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) announced that CMS assigned VNS Therapy for drug-resistant epilepsy to New Technology APC 1580 for new patient implants and moved end-of-service procedures to Level 5 APC, effective Jan. 1, 2026. CMS will increase hospital outpatient payments by about 48% for NPIs and 47% for EOS versus 2025 rates. LivaNova said the reimbursement change should improve hospital economics, reduce a barrier to procedure penetration, and expand patient access to VNS Therapy, which the company reports showed median seizure reductions of 80% and 95% in CORE-VNS at 36 months.
LivaNova (Nasdaq: LIVN) presented a strategic roadmap and 2030 financial targets at its 2025 Investor Day on November 12, 2025.
Key targets include high-single-digit-plus revenue CAGR to 2030, adjusted operating margin above 20% over the next three years and targeting high‑twenties by 2030, EPS CAGR in the low double digits to mid‑teens, and adjusted free cash flow conversion above 80%.
Growth pillars are maximizing Cardiopulmonary and Epilepsy cores, scaling Obstructive Sleep Apnea (OSA) with an independent U.S. commercial launch planned for 2027, and optional upside from Difficult‑to‑Treat Depression contingent on CMS coverage. OSA is projected to reach $200M–$400M revenue by 2030 and >25% adjusted operating margin, with break‑even expected by 2029.